Literature DB >> 2472136

Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases.

E L White1, W B Parker, L J Macy, S C Shaddix, G McCaleb, J A Secrist, R Vince, W M Shannon.   

Abstract

Carbocylic 2',3'-didehydro-2',3'-dideoxyguanosine (Carbovir; NSC 614846) is an antiretroviral agent which may be useful in the treatment of AIDS. We have synthesized the 5'-triphosphate of Carbovir and examined its ability to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (EC 2.7.7.49) and other retroviral reverse transcriptases, as well as human DNA polymerases alpha, beta, gamma (EC 2.7.7.7) and DNA primase (EC 2.7.7.6). Carbovir triphosphate emerges as a highly selective inhibitor of reverse transcriptases with little, if any, effect on the cellular enzymes. 3'-Azido-2',3'-dideoxythymidine (AZT) triphosphate and the two dideoxynucleoside triphosphates, ddTTP and ddGTP, inhibited HIV-1 reverse transcriptase to the same degree as Carbovir triphosphate, but were less selective in that they also inhibited DNA polymerases beta and gamma. We conclude that Carbovir is a highly selective antiretroviral agent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472136     DOI: 10.1016/0006-291x(89)92611-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine.

Authors:  M N Prichard; L E Prichard; W A Baguley; M R Nassiri; C Shipman
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 2.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro.

Authors:  S G Carter; J A Kessler; C D Rankin
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism.

Authors:  W B Parker; S C Shaddix; B J Bowdon; L M Rose; R Vince; W M Shannon; L L Bennett
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

Review 5.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

6.  The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  P A Furman; M Davis; D C Liotta; M Paff; L W Frick; D J Nelson; R E Dornsife; J A Wurster; L J Wilson; J A Fyfe
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

7.  Intestinal absorption of (-)-carbovir in the rat.

Authors:  I Soria; C L Zimmerman
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

8.  Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma.

Authors:  G J Hart; D C Orr; C R Penn; H T Figueiredo; N M Gray; R E Boehme; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

9.  The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase.

Authors:  J E Wilson; J L Martin; K Borroto-Esoda; S Hopkins; G Painter; D C Liotta; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

10.  Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1.

Authors:  M S Smith; J A Kessler; C D Rankin; J S Pagano; J Kurtzberg; S G Carter
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.